Halma has made a strategic investment in Valencell, a leading innovator in wearable sensor technology.
Valencell’s biometric sensor technology provides highly accurate measurements of heart rate, blood pressure and other biometrics, which can be used in medical-grade wearables.
Valencell has established a strong position at the convergence of the consumer wearables and health and medical devices markets. The company’s technology has been integrated into more than 50 different devices that have come to market around the world. It also holds a comprehensive patent portfolio in wearable photoplethysmography (PPG) – which measures a variety of blood flow characteristics – with over 85 granted patents and more than 100 additional patents pending.
Halma has taken a minority equity stake and a seat on the board, which will enable Valencell to accelerate its growth opportunities. The partnership will also bring new capabilities to companies within Halma’s Medical sector already operating in this market niche. SunTech Medical, a Halma company, has signed a collaboration agreement with Valencell to co-operate on a clinical-grade blood pressure technology augmented with a PPG sensor.
In addition to Halma’s investment in this round, other new investors include Novo Holdings and existing investors TDF Ventures, GII LLC, and WSJ Joshua Fund.